Literature DB >> 16081936

Early immune response to the components of the type III system of Pseudomonas aeruginosa in children with cystic fibrosis.

R Corech1, A Rao, A Laxova, J Moss, M J Rock, Z Li, M R Kosorok, M L Splaingard, P M Farrell, J T Barbieri.   

Abstract

The lungs of patients with cystic fibrosis (CF) are colonized initially by Pseudomonas aeruginosa, which is associated with progressive lung destruction and increased mortality. The pathogenicity of P. aeruginosa is caused by a number of virulence factors, including exotoxin A (ETA) and the type III cytotoxins (ExoS, ExoT, ExoU, and ExoY). P. aeruginosa contacts the plasma membrane to deliver type III cytotoxins through a channel formed by PopB, PopD, and PcrV; ETA enters mammalian cells via receptor-mediated endocytosis. The Wisconsin CF Neonatal Screening Project is a longitudinal investigation to assess the potential benefits and risks of newborn screening for CF; the project was the source of serum samples used in this study. Past studies evaluated the longitudinal appearance of antibodies to ETA and elastase and P. aeruginosa infections in patients with CF. The current study characterized the longitudinal appearance of antibodies to components of the type III system in children with CF. Western blot analyses showed that serum antibodies to PopB, PcrV, and ExoS were common. Longitudinal enzyme-linked immunosorbent assays determined that the first detection of antibodies to pooled ExoS/PopB occurred at a time similar to those of detection of antibodies to a P. aeruginosa cell lysate and the identification of oropharyngeal cultures positive for P. aeruginosa. This indicates that children with CF are colonized early with P. aeruginosa expressing the type III system, implicating it in early pathogenesis, and implies that surveillance of clinical symptoms, oropharyngeal cultures, and seroconversion to type III antigens may facilitate early detection of P. aeruginosa infections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16081936      PMCID: PMC1233990          DOI: 10.1128/JCM.43.8.3956-3962.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   11.677


  42 in total

1.  Cloning and sequence analysis of a trans-regulatory locus required for exoenzyme S synthesis in Pseudomonas aeruginosa.

Authors:  D W Frank; B H Iglewski
Journal:  J Bacteriol       Date:  1991-10       Impact factor: 3.490

2.  Conversion of Pseudomonas aeruginosa to the phenotype characteristic of strains from patients with cystic fibrosis.

Authors:  D P Speert; S W Farmer; M E Campbell; J M Musser; R K Selander; S Kuo
Journal:  J Clin Microbiol       Date:  1990-02       Impact factor: 5.948

3.  Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis.

Authors:  D S Armstrong; K Grimwood; J B Carlin; R Carzino; A Olinsky; P D Phelan
Journal:  Pediatr Pulmonol       Date:  1996-05

4.  Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis.

Authors:  B Frederiksen; C Koch; N Høiby
Journal:  Pediatr Pulmonol       Date:  1997-05

5.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

6.  Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization.

Authors:  J Hill; S E Leary; K F Griffin; E D Williamson; R W Titball
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

7.  Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group.

Authors:  P M Farrell; M R Kosorok; A Laxova; G Shen; R E Koscik; W T Bruns; M Splaingard; E H Mischler
Journal:  N Engl J Med       Date:  1997-10-02       Impact factor: 91.245

8.  Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients.

Authors:  B W Ramsey; K R Wentz; A L Smith; M Richardson; J Williams-Warren; D L Hedges; R Gibson; G J Redding; K Lent; K Harris
Journal:  Am Rev Respir Dis       Date:  1991-08

9.  The changing epidemiology of cystic fibrosis.

Authors:  S C FitzSimmons
Journal:  J Pediatr       Date:  1993-01       Impact factor: 4.406

10.  Relation between antibody response to Pseudomonas aeruginosa exoproteins and colonization/infection in patients with cystic fibrosis.

Authors:  M Granström; A Ericsson; B Strandvik; B Wretlind; O R Pavlovskis; R Berka; M L Vasil
Journal:  Acta Paediatr Scand       Date:  1984-11
View more
  15 in total

1.  Pseudomonas serology: confusion, controversy, and challenges.

Authors:  P M Farrell; J R W Govan
Journal:  Thorax       Date:  2006-06-12       Impact factor: 9.139

Review 2.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 3.  Virulence attenuating combination therapy: a potential multi-target synergy approach to treat Pseudomonas aeruginosa infections in cystic fibrosis patients.

Authors:  Elana Shaw; William M Wuest
Journal:  RSC Med Chem       Date:  2020-02-19

4.  Chest computed tomography scores of severity are associated with future lung disease progression in children with cystic fibrosis.

Authors:  Don B Sanders; Zhanhai Li; Alan S Brody; Philip M Farrell
Journal:  Am J Respir Crit Care Med       Date:  2011-10-01       Impact factor: 21.405

Review 5.  Toxins from bacteria.

Authors:  James S Henkel; Michael R Baldwin; Joseph T Barbieri
Journal:  EXS       Date:  2010

6.  Characterization of hydrogen peroxide production by Duox in bronchial epithelial cells exposed to Pseudomonas aeruginosa.

Authors:  Balázs Rada; Thomas L Leto
Journal:  FEBS Lett       Date:  2010-01-19       Impact factor: 4.124

7.  Association between mucoid Pseudomonas infection and bronchiectasis in children with cystic fibrosis.

Authors:  Philip M Farrell; Jannette Collins; Lynn S Broderick; Michael J Rock; Zhanhai Li; Michael R Kosorok; Anita Laxova; William M Gershan; Alan S Brody
Journal:  Radiology       Date:  2009-08       Impact factor: 11.105

8.  Pseudomonas aeruginosa Bacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide.

Authors:  Joshua T Thaden; Ashley E Keller; Norah J Shire; M Margarita Camara; Linda Otterson; Mike Huband; Caitlin M Guenther; Wei Zhao; Paul Warrener; C Kendall Stover; Vance G Fowler; Antonio DiGiandomenico
Journal:  J Infect Dis       Date:  2015-09-02       Impact factor: 5.226

9.  Microarray analysis of the osmotic stress response in Pseudomonas aeruginosa.

Authors:  Arden Aspedon; Kelli Palmer; Marvin Whiteley
Journal:  J Bacteriol       Date:  2006-04       Impact factor: 3.490

10.  Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial.

Authors:  Michael Anstead; Sonya L Heltshe; Umer Khan; Joseph T Barbieri; Markus Langkamp; Gerd Döring; Shimoni Dharia; Ronald L Gibson; Miriam M Treggiari; James Lymp; Margaret Rosenfeld; Bonnie Ramsey
Journal:  J Cyst Fibros       Date:  2012-09-01       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.